Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML) remains undefined. We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/k...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Pidala, Joseph, Kim, Jongphil, Anasetti, Claudio, Kharfan-Dabaja, Mohamed A, Nishihori, Taiga, Field, Teresa, Perkins, Janelle, Perez, Lia, Fernandez, Hugo F
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2010
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2958877/
https://ncbi.nlm.nih.gov/pubmed/20925957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-36
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak